Why Structure Therapeutics Stock Doubled and Then Some on Monday
Structure Therapeutics(US:GPCR) The Motley Fool·2025-12-09 00:55The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure Therapeutics (GPCR +102.49%), skyrocketed almost 103% higher in price that day on some highly promising data produced by its weight-loss candidate medication. A successful studyStructure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP ...